Accelerating translational life sciences from lab to clinic

We invest in Pre-Seed and Seed stage BioTech and MedTech startups that have demonstrated substantial translational progress with non-dilutive funding. We partner with scientists who have validated their science and are ready to build translational companies.


Portfolio

Seed · 2026

Clinical-stage company developing non-invasive ultrasound neuromodulation to treat chronic inflammatory disorders by activating the body's natural anti-inflammatory pathways.

Medical Device Neuromodulation

Pre-Seed · 2025

Developing the first injectable electrode platform for cardiac rhythm management, using conductive hydrogel to restore electrical conduction across scarred myocardium and enable low-energy, painless defibrillation.

Medical Device Cardiovascular

Volumetric

YC W20
Exited

Personal Investment · 2019

Rice spinout developing bioprinting for vascular tissue structures.

Acquired by 3D Systems

Regenerative Medicine Bioprinting